SARS-CoV-2 variants tagged posts

Researchers at Karolinska Institutet and Danderyd Hospital have followed recipients of the new updated COVID-19 vaccine and analyzed the antibody response to different SARS-CoV-2 variants. The results show a surprisingly strong response to the now dominant and highly mutated omicron variants.

The ongoing COMMUNITY study, which was launched in the spring of 2020 with the regular testing of 2,149 members of the Danderyd Hospital staff, has recently published the results of this autumn’s leg of the study.

Twenty-four participants were recorded in this study, the majority of whom were over 64 and had received four or five previous vaccine doses...

Researchers chart course for the design, testing, and implementation of next-gen AI in medicine.

Most medical AI models in use today are trained to perform one or two specific tasks and have limited utility. Next-generation AI — called generalist medical AI — incorporates various types of data to perform a variety of complex tasks in a range of clinical scenarios. Generalist medical AI can reshape medicine by augmenting clinical decision-making, real-time surgical and bedside support, and more.

The vast majority of AI models used in medicine today are “narrow specialists,” trained to perform one or two tasks, such as scanning mammograms for signs of breast cancer or detecting lung disease on chest X-rays.

But the everyday practice of medicine involves an endless array of clin...

A team led by researchers at Weill Cornell Medicine, the University of Wisconsin-Madison; Scripps Research and the University of Chicago has identified an antibody that appears to block infection by all dominantvariants of the virus that causes COVID-19, including Omicron, the most recent. Their discovery could lead to more potent vaccines and new antibody-based treatments.

In a study published March 6 in the Journal of Clinical Investigation, senior author Dr. Patrick Wilson, the Anne E...

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike protein that remain essentially unchanged as the viruses mutate.

By identifying the targets of these “broadly neutralizing” antibodies on the spike protein, it might be possible to design vaccines and antibody treatments that will be effective against not only the omicron variant but other variants that may emerge in the future, said David Veesler, investigator with the Howard Hughes Medical Institute and associate professor of biochemistry at the University of Washington School of Medicine in Seattle...